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Hypothesis:  Healthcare system/provider biases and differences in patient characteristics are 
thought to be prevailing factors underlying racial disparities.  The influence of these factors on 
the receipt of care would likely be mitigated among patients recommended optimal therapy.  We 
hypothesized that there would be no significant evidence of racial disparities among early-stage 
lung cancer patients recommended surgical therapy. 
 
Design:  Retrospective cohort study. 
 
Patients and Setting:  Patients within the Surveillance, Epidemiology, and End-Results-
Medicare database diagnosed with stage I or II lung cancer between 1992 and 2002 (follow-up 
through 2005). 
 
Main Outcome Measures:  Receipt of lung resection and overall survival. 
 
Results:  Among 17,739 patients recommended surgical therapy—mean (SD) age 75 (5) years, 
89% white, 6% black—blacks less frequently underwent resection compared to whites (69% 
versus 83%, p<0.001).  After adjustment, black race was associated with a lower odds of 
receiving surgical therapy (OR 0.43, 99% CI 0.36-0.52).  Unadjusted 5-year survival rates were 
lower for blacks compared to whites (36% versus 42%, p<0.001).   After adjustment, there was 
no significant association between race and death (HR 1.03, 99% CI 0.92-1.14) despite a 14% 
difference in receipt of optimal therapy. 
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Conclusions:  Even among patients recommend surgical therapy, blacks underwent lung 
resection less often then whites.  Unexpectedly, racial differences in the receipt of optimal 
therapy did not appear to affect outcomes.  These findings suggest that distrust, beliefs and 
perceptions about lung cancer and its treatment, and limited access to care (despite insurance) 





















Lung cancer is the second most common malignancy in the US and is responsible for 
more deaths than any other cancer.1    Pulmonary resection provides the best chance of cure for 
patients with early-stage disease.2-4  Blacks with early-stage lung cancer have lower 5-year 
survival rates than whites, and this difference in outcome has been attributed to lower rates of 
resection among blacks.5  
Barriers to the receipt of optimal cancer therapy are likely numerous and complex.6  
Several potential factors underlying racial differences in the receipt of surgical therapy include 
differences in pulmonary function7, access to care8, refusal of surgery9, beliefs about tumor 
spread upon air exposure at the time of operation10 and the possibility of cure without surgery11, 
distrust of the health care system/physicians12, suboptimal patterns of patient/physician 
communication13,  and health care system/provider biases.14, 15  Differences in patient 
characteristics (i.e. lung function, performance status, severity of comorbidity) and healthcare 
system/provider bias are often argued to be significant factors underlying racial disparities.   
To better understand the relationship between hypothesized factors and racial differences 
in care and outcomes, we conducted a cohort study using the Surveillance, Epidemiology, and 
End-Results (SEER)-Medicare database. Among patients recommended surgical therapy, the 
effects of healthcare system/provider biases on the receipt of optimal care might be mitigated, as 
might the potentially confounding effects of some measured and unmeasured patient 
characteristics.  We hypothesized that resection and survival rates would not vary between 





A retrospective cohort study was conducted of patients diagnosed with lung cancer 
between 1992 and 2002.  The use of SEER-Medicare to investigate cancer care, and the quality 
and validity of variables therein, have been described extensively elsewhere.16-22  The University 
of Washington Institutional Review Board approved this study, and waived consent because the 
investigation involved existing, de-identified data. 
Among 221,208 patients diagnosed with lung cancer between 1992 and 2002, sequential 
exclusions were made for the following patients: advanced stage of disease or missing stage data 
(n=177,910), diagnosis at autopsy or death (n=134), age less than 66 years (n=9,284), diagnosis 
of a second malignancy up to 6 months after lung cancer diagnosis (n=1,333), partial fee-for-
service Medicare coverage and/or concurrent enrollment in a health maintenance organization 
(n=10,389), or a histology code inconsistent with lung cancer (n=32).  An additional 4,387 
patients who were not recommended surgical therapy (19% of whites and 26% of blacks) were 
excluded from the analysis for a final cohort of 17,739 patients. 
SEER data abstractors examined medical records to determine whether surgical therapy 
was recommended.23  In this study, patients were considered to have been recommended surgical 
therapy if there was a documented recommendation in the medical records and/or if the patient 
underwent surgical therapy.  
Race was the main predictor variable, ascertained using the Medicare Enrollment 
Database, and classified as white, black, or other based on a prior recommendation.17  Income 
and education level were based on quartiles of median income and proportion of people with 
only a high-school education living in the patient’s zip code at the time of diagnosis.  Geography 
was determined by the location of the SEER registry.  Residence refers to the size of the 
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population where the patient lived (metropolitan ≥ 250,000; urban 20,000-249,999, and rural 
<19,999).  The previously validated Klabunde-modified Charlson comorbidity index was derived 
from Carrier and Outpatient claims in the year prior to diagnosis.24  Stage was based on the 6th 
edition of the American Joint Committee on Cancer staging manual. 
Outcomes included resection and overall survival.  Resection, radiation therapy, and 
chemotherapy were ascertained up to 6 months after diagnosis using The Healthcare Common 
Procedure Coding System, International Classification of Diseases procedure codes, and 
Revenue Center Codes, as appropriate, in the Carrier Claim and Outpatient files (codes available 
upon request).  Death information was available in the Medicare Enrollment Database with 
follow-up through 2005. 
Differences in continuous and categorical variables between blacks and whites were 
tested using t-tests for independent samples and the chi-square, respectively.  Logistic regression 
was used to evaluate whether an association existed between race and the receipt of resection 
after adjustment for potentially confounding factors.  Unadjusted differences in overall survival 
were estimated using the Kaplan-Meier method.  Cox proportional hazards (PH) models were 
used to evaluate the unadjusted and adjusted relationships between race and survival.  
Schoenfeld residuals were used to test the PH assumption and extended (stratified) Cox models 
were fitted if the PH assumption was violated.  Survival time was defined by the interval 
between date of diagnosis and date of death or censoring.  Robust variance estimators were used 
for all regression analyses.  All regression analyses were case-complete analyses.  Seven percent 
of patients had at least one missing covariate value.  The proportion of patients with missing 
covariate data did not vary between blacks and whites (7% versus 7%, p=0.82), and patients with 
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missing covariate data did not have a lower 5-year survival rate compared to those with no 
missing data (42% versus 42%, p=0.46). 
Several post-hoc sensitivity analyses were conducted.  The relationship between race and 
receipt of surgical therapy would ideally be characterized in terms of relative risks or risk 
differences, but generalized linear models estimating relative risks and risk differences could not 
be fit.  Results from the logistic regression analysis were re-examined after converting odds 
ratios to relative risks.   When event rates are high, as was the case in this investigation (receipt 
of surgical therapy), an odds ratio tends to overestimate the risk ratio.25  The relationship 
between race and receipt of surgical therapy was also re-evaluated in a time-to-event analysis 
censoring for deaths occurring among untreated patients within 6-months of diagnosis.  If rates 
of death between diagnosis and treatment varied by race, then the results of the primary analysis 
might have been biased.  Finally, all regression analyses were repeated after adjustment for 
clustering within SEER registry because practice patterns might have been highly correlated 
within a given SEER registry.  Adjustment for clustering at the provider or institution level was 
not possible because not all patients underwent surgical therapy and some patients received no 
therapy at all. 
STATA (Special Edition 9.2, Statacorp, College Station, Texas) was used for all 
statistical analyses.  A two-sided p-value of <0.01 was considered statistically significant. 
 
RESULTS 
A total of 17,739 patients with stage I/II lung cancer—median (range) age 74 (66-103) 
years, 89% white, and 6% black—were recommended surgical therapy (Table 1).  Compared to 
whites, blacks were more frequently men, in the lowest quartiles of income and education, not 
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married at the time of diagnosis, residing in a metropolitan area, and had comorbid conditions.  
Racial differences in the distributions of stage  and histology were not significant . 
Blacks underwent lung resection less frequently than whites (69% versus 83%, difference 
14%, 99% CI 11-18%) despite both groups having been recommended surgical therapy (Table 2).  
Among those who did not undergo resection, there was no significant difference in the 
proportion of blacks versus whites who underwent medical management (36% vs. 40%, p=0.26).  
After accounting for the potential confounding effects of variables listed in Table 1, blacks had a 
55% lower odds of having received a lung resection compared to whites (Table 3).  This 
association persisted in all sensitivity analyses though the magnitude of the association was 
attenuated in some cases: odds ratios converted to relative risk (adjusted relative risk 0.83, 99% 
CI 0.78-0.88), censoring for early death (adjusted hazard ratio (HR) 0.67, 99% CI 0.60-0.75), 
adjustment for clustering within SEER registries (adjusted odds ratio (OR) 0.45, 99% CI 0.34-
0.60). 
Blacks had a lower unadjusted 5-year overall survival rate compared to whites  (36% vs. 
42%, p<0.001).  After adjusting for patient and disease characteristics, only a small and non-
significant association between black race and death was evident (Table 3), despite the fact that 
blacks underwent resection 14% less often than whites.  This lack of association between race 
and death persisted in a sensitivity analysis adjusting for clustering within SEER registries 
(adjusted hazard ratio 1.03, 99% CI 0.93-1.13).  In an exploratory analysis, treatment received 
(including no therapy) was added to the model to investigate whether race had an effect on death 
through a pathway unrelated to the receipt of therapy.  Blacks had a 6% lower hazard of death 
compared to whites, though this association was not significant (adjusted HR 0.94, 99% 0.82-
1.09).  In another exploratory analysis, lung-cancer cause-specific survival rates were evaluated 
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though there was no racial variation in outcomes in the unadjusted (62% vs 64%, p=0.17) or 
adjusted (HR 1.01, 99% CI 0.88-1.17) analyses. 
 
DISCUSSION 
Multiple factors likely result in racial differences in care and outcomes among early-stage 
lung cancer patients, but the impact of any one factor(s) on overall differences is not well 
understood.  Healthcare system/provider biases and differences in patient characteristics are 
often thought to be predominant factors underlying racial disparities.  Accordingly, we 
hypothesized that the influence of these factors on the receipt of optimal therapy would be 
mitigated among patients recommended surgical therapy, and therefore we did not expect 
significant racial variation in lung resection or outcomes.  This investigation is the first to 
describe care and outcomes among early-stage lung cancer patients recommended surgical 
therapy using a nationally representative database.  Contrary to expectation, we observed a large 
(14%) difference between blacks and whites in the proportion of patients who actually 
underwent lung resection even though all patients were recommended surgical therapy.  Another 
surprising finding was that this large difference in receipt of optimal therapy did not appear to 
affect long-term survival after adjustment for patient and disease characteristics.  These findings 
suggest that reasons other than healthcare system/provider biases and patient characteristics may 
play a larger role in creating racial disparities than previously recognized. 
There are several possible explanations for why large racial differences in care were 
observed among lung cancer patients recommended surgical therapy.  Blacks have been shown 
to refuse surgical therapy more frequently than whites for reasons relating to beliefs about 
accelerated tumor spread at the time of operation10, the possibility of cure without resection11, 
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and distrust of the healthcare system and providers.12  Though refusal rates have been reported as 
high as 18% among blacks9, the generalizability of that finding is uncertain because the 
proportion of blacks in that study was higher than that reported in nationally representative 
cohorts (35% vs. 10%).26  The current study could not determine why patients did not receive 
surgical therapy, but the findings are consistent with the notion that refusal rates among lung 
cancer patients may be high and higher among blacks.  Another explanation for why blacks 
underwent lung resection less frequently than whites is limited access to care.  All patients in this 
study had uniform health insurance and demonstrated the ability to utilize health services—as 
evidenced by a documented diagnosis and treatment recommendation—but not all patients may 
have had access to care facilities and/or providers able to provide optimal cancer therapy.    
Supporting that notion, a study of Medicare beneficiaries found that primary care physicians 
treating black patients had less access to high-quality sub-specialists compared to physicians 
treating white patients.27  A third explanation for racial differences in care is that healthcare 
system/provider biases may exist even in a setting where optimal therapy is recommended.   
Studies evaluating patients with a diagnosis of lung cancer or a pulmonary nodule found that 
patients in racially discordant physician-patient pairs received less information and were less 
often prompted to actively participate in conversation compared to patients in racially concordant 
pairs.13  Additionally, black patients trusted their physician less often than white patients after an 
initial visit with a surgeon or oncologist, and this distrust appeared to be linked to perceptions 
that physician communication was not supportive, partnering, or informative.12  Finally, 
hypothesized factors not measured in the current study or previously investigated—such as racial 
variation in distance/travel or family/social support6—might also explain racial differences in the 
receipt of lung resection.   
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Despite large racial differences in the receipt of optimal therapy, there were no 
observable differences in survival between blacks and whites.  This finding is seemingly 
implausible because it is contrary to conventional wisdom, practice guidelines, and empirical 
evidence.  Among all SEER-Medicare patients with stage I/II lung cancer, stage-based survival 
rates were significantly higher for patients who received operative therapy compared those who 
did not (Stage I: 50% vs. 15%, p<0.001; Stage II (28% vs. 8%, p<0.001).  Inadequate risk-
adjustment provides one explanation for this unexpected finding.  The relationship between race 
and survival may have been confounded by unmeasured patient selection factors.  For instance, 
forced expiratory volume is strongly associated with both the receipt of surgical therapy and 
survival and may vary by race.7  No racial difference in survival might be observed if operated 
white patients were at higher-risk (defined by poorer pulmonary function) for death compared to 
operated black patients—counterbalancing the effect of more lung resections among whites 
compared to blacks.  Since SEER-Medicare does not record detailed information about patient 
selection, this study may not have provided adequate adjustment for all potential confounders—
including forced expiratory volume, performance status, and severity of comorbid conditions.  
To the extent that this explanation is true, the issue of overuse and underuse of therapy is 
important to consider.28  Surgical therapy may have been “overused” among whites or it may 
have been “underused” among blacks, although this determination cannot be made because 
practice guidelines recommendations are not based on risk-stratification.2   
The major limitation of this study is concern over the accuracy and validity of the 
“recommended surgery” variable within SEER.  Although SEER data is considered highly 
valid22, there are no published third-party evaluations of the validity and accuracy of this variable.  
The face validity of this variable could be evaluated because the recommendation to undergo 
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surgical therapy and receipt of surgical therapy were ascertained by two independent sources—
SEER and Medicare, respectively.   While it is plausible that a patient who is recommended 
surgical therapy might or might not actually undergo resection, it is not likely that patients not 
recommended surgical therapy would undergo resection.  Among patients not recommended 
surgical therapy, only 1% underwent resection and this proportion did not vary by race.  One 
shortcoming of this variable is an inability to identify the type of provider (surgeon, oncologist, 
pulmonologist, etc.) who made the recommendation and/or the context (both clinical and 
cultural) in which the recommendation was made.  Another limitation of this study is that our 
findings may only be generalizable to elderly, Medicare beneficiaries.  However, given that the 
median age at diagnosis of lung cancer is 70 years old26 and that Medicare provides health care 
coverage for over 97% of Americans over 65 years of age, this study might be considered to be 
representative of most lung cancer patients.  Although evidence shows that other racial groups, 
such as Hispanics, have disparate care and outcomes29, we were not able to evaluate other racial 
groups because prior studies indicate that SEER and/or Medicare only reliably measure black or 
white race.17 
In conclusion, even among early-stage lung cancer patients recommended surgical 
therapy there was large racial variation in the receipt of optimal cancer treatment after 
adjustment and despite uniform healthcare coverage.  While these findings do not refute the 
likely roles of healthcare system/provider biases and patient characteristics as important causal 
factors underlying health disparities, the findings do suggest that other factors (i.e. distrust, 
perceptions and beliefs about lung cancer and its treatment, and limited access to sub-specialty 
care) may have a more dominant role in causing disparities than previously recognized.  The 
implication of these findings is that interventions designed to narrow gaps in healthcare should 
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target both structural aspects of care and providers, patients, and communities at risk for lung 
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Age, No. (%), y   < 0.001 
  66-70 4,103 (26) 368 (34)  
  71-75 5,223 (33) 366 (33)  
  76-80 4,071 (26) 236 (22)  
  81-85 1,789 (11) 103 (9)  
  86+ 540 (3) 23 (2)  
  mean (SD) 75 (5) 74 (5) < 0.001 
    
Male, No. (%) 8,279 (53) 629 (57) 0.002 
    
Income, No. (%)   < 0.001 
  Lowest Quartile 3,180 (20) 639 (58)  
  Missing 593 (4) 28 (3)  
    
Education, No. (%)   < 0.001 
  Lowest Quartile 2,965 (19) 712 (65)  












Marital Status, No. (%)   < 0.001 
  Unmarried 6,051 (39) 580 (53)  
  Missing 526 (3) 47 (4)  
    
Geography, No. (%)   < 0.001 
  West 6,839 (44) 331 (30)  
  East 2,751 (18) 138 (13)  
  Midwest 4,173 (27) 449 (41)  
  South 1,963 (13) 178 (16)  
    
Residence, No. (%)   < 0.001 
  Metropolitan 13,399 (85) 1,059 (97)  
  Urban 963 (6) 13 (1)  
  Rural 1,364 (9) 24 (2)  
    














Comorbidity Index, No. (%)   < 0.001 
  0 8,758 (58) 544 (50)  
  1 4,545 (29) 310 (28)  
  2 1,572 (10) 143 (13)  
  3+ 851 (5) 99 (9)  
    
Stage, No. (%)   0.09 
  IA 6,550 (42) 450 (41)  
  IB 6,335 (40) 475 (43)  
  IIA 591 (4) 31 (3)  
  IIB 2,250 (14) 140 (13)  
    
Histology, No. (%)   0.009 
  Non-Small Cell 14,136 (90) 993 (91)  
  Small Cell 327 (2) 27 (3)  
  Not-Otherwise-Specified 691 (4) 56 (5)  
  Other* 572 (4) 20 (2)  
 
*Includes carcinoid tumors, sarcomas, and other rare histologic typ
Table 2.  Racial Variation in Treatment and Outcomes Among Patients  







    
Therapy, No. (%)   < 0.001 
  Resection 13,112 (83) 756 (69)  
  Radiation Therapy 606 (4) 69 (6)  
  Chemotherapy 150 (1) 26 (2)  
  Chemoradiation Therapy 280 (2) 29 (3)  
  None 1,578 (10) 216 (20)  
    
5-Year Survival, % (99% CI)    
  Stage I 46 (45-47) 39 (35-43) < 0.001 
  Stage II 25 (23-27) 18 (10-26) 0.21 
  Overall 41 (41-43) 36 (32-40) < 0.001 
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Table 3.  Multivariate Analyses of the Relationship Between Race, Treatment, and  
   Outcomes Among Patients Recommended Surgical Therapy 
 
 Lung Resection Death 
 Odds Ratio (99% CI) Hazard Ratio (99% CI) 
Black versus White   
  Unadjusted 0.43 (0.36-0.52) 1.17 (1.06-1.29) 
  Add Patient Characteristicsa 0.47 (0.38-0.57) 1.04 (0.94-1.16) 
  Add Cancer Characteristicsb 0.45 (0.37-0.56) 1.03 (0.92-1.14) 
   
 
aAdjusted for age, sex, income, education, marital status, geography, area of residence, prior malignancy, and comorbidity index 
bAdjusted for histology and stage 
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